Nautilus Biotechnology (NAUT) Non-Current Deffered Revenue (2020 - 2021)
Nautilus Biotechnology (NAUT) reported Non-Current Deffered Revenue of $5.2 million for Q1 2021, little changed sequentially from $5.2 million in Q4 2020.
Nautilus Biotechnology (NAUT) Non-Current Deffered Revenue (2020 - 2021) Analysis & Trends
Nautilus Biotechnology (NAUT) has 2 years of Non-Current Deffered Revenue data on file, last reported at $5.2 million in Q1 2021.
- For the quarter ending Q1 2021, Non-Current Deffered Revenue changed N/A year-over-year to $5.2 million; the trailing twelve-month figure through Mar 2021 stood at $5.2 million (changed N/A YoY), and the FY2020 full-year result was $5.2 million, changed N/A from the prior year.
- Non-Current Deffered Revenue was little changed at $5.2 million in Q1 2021, from $5.2 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $5.2 million in Q3 2020 to a low of $5.2 million in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Nautilus Biotechnology | 224.14 Mn | 224.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 5.23 Mn |
| Dec 31, 2020 | 5.23 Mn |
| Sep 30, 2020 | 5.23 Mn |